Literature DB >> 24421519

Docetaxel and Cisplatin regimen for non-small-cell lung cancer.

Jessie Yang1, Dominic A Solimando1, J Aubrey Waddell1.   

Abstract

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr., President, Oncology Pharmacy Services, Inc., 4201 Wilson Blvd #110-545, Arlington, VA 22203, e-mail: OncRxSvc@aol.com; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net.

Entities:  

Year:  2013        PMID： 24421519      PMCID： PMC3839522          DOI： 10.1310/hpj4807-550

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  28 in total

1.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Authors:  Rafael Rosell; Enric Carcereny; Radj Gervais; Alain Vergnenegre; Bartomeu Massuti; Enriqueta Felip; Ramon Palmero; Ramon Garcia-Gomez; Cinta Pallares; Jose Miguel Sanchez; Rut Porta; Manuel Cobo; Pilar Garrido; Flavia Longo; Teresa Moran; Amelia Insa; Filippo De Marinis; Romain Corre; Isabel Bover; Alfonso Illiano; Eric Dansin; Javier de Castro; Michele Milella; Noemi Reguart; Giuseppe Altavilla; Ulpiano Jimenez; Mariano Provencio; Miguel Angel Moreno; Josefa Terrasa; Jose Muñoz-Langa; Javier Valdivia; Dolores Isla; Manuel Domine; Olivier Molinier; Julien Mazieres; Nathalie Baize; Rosario Garcia-Campelo; Gilles Robinet; Delvys Rodriguez-Abreu; Guillermo Lopez-Vivanco; Vittorio Gebbia; Lioba Ferrera-Delgado; Pierre Bombaron; Reyes Bernabe; Alessandra Bearz; Angel Artal; Enrico Cortesi; Christian Rolfo; Maria Sanchez-Ronco; Ana Drozdowskyj; Cristina Queralt; Itziar de Aguirre; Jose Luis Ramirez; Jose Javier Sanchez; Miguel Angel Molina; Miquel Taron; Luis Paz-Ares
Journal:  Lancet Oncol       Date:  2012-01-26       Impact factor: 41.316

2.  2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

Authors:  Thomas J Smith; James Khatcheressian; Gary H Lyman; Howard Ozer; James O Armitage; Lodovico Balducci; Charles L Bennett; Scott B Cantor; Jeffrey Crawford; Scott J Cross; George Demetri; Christopher E Desch; Philip A Pizzo; Charles A Schiffer; Lee Schwartzberg; Mark R Somerfield; George Somlo; James C Wade; James L Wade; Rodger J Winn; Antoinette J Wozniak; Antonio C Wolff
Journal:  J Clin Oncol       Date:  2006-05-08       Impact factor: 44.544

Review 3.  Hepatotoxicity of chemotherapy.

Authors:  P D King; M C Perry
Journal:  Oncologist       Date:  2001

4.  Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic or unresectable localized non-small-cell lung cancer.

Authors:  Yeul H Kim; Jun S Kim; Young H Choi; Kwang H In; Hee S Park; Dae S Hong; Tae J Jeong; Young Y Lee; Eunmi Nam; Soon N Lee; Kyung S Lee; Hoon K Kim
Journal:  Int J Clin Oncol       Date:  2002-04       Impact factor: 3.402

5.  A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of cancer and leukemia group B Trial 9780.

Authors:  D Savarese; M E Taplin; S Halabi; V Hars; W Kreis; N Vogelzang
Journal:  Semin Oncol       Date:  1999-10       Impact factor: 4.929

6.  Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer.

Authors:  E H Tan; J Rolski; T Grodzki; C P Schneider; U Gatzemeier; P Zatloukal; E Aitini; G Carteni; H Riska; Y H Tsai; R Abratt
Journal:  Ann Oncol       Date:  2009-03-10       Impact factor: 32.976

7.  Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group.

Authors:  Kaoru Kubota; Koshiro Watanabe; Hideo Kunitoh; Kazumasa Noda; Yukito Ichinose; Nobuyuki Katakami; Takahiko Sugiura; Masaaki Kawahara; Akira Yokoyama; Soichiro Yokota; Shuichi Yoneda; Kaoru Matsui; Shinzo Kudo; Masahiko Shibuya; Takeshi Isobe; Yoshihiko Segawa; Yutaka Nishiwaki; Yasuo Ohashi; Hisanobu Niitani
Journal:  J Clin Oncol       Date:  2004-01-15       Impact factor: 44.544

Review 8.  Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function.

Authors:  P E Kintzel; R T Dorr
Journal:  Cancer Treat Rev       Date:  1995-01       Impact factor: 12.111

Review 9.  Hepatotoxicity of chemotherapy.

Authors:  Justin Floyd; Irfan Mirza; Bradley Sachs; Michael C Perry
Journal:  Semin Oncol       Date:  2006-02       Impact factor: 4.929

Review 10.  Anticancer drug-induced kidney disorders.

Authors:  P E Kintzel
Journal:  Drug Saf       Date:  2001-01       Impact factor: 5.228
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.